/SVRA
SVRA Stock - Savara Inc.
Healthcare|BiotechnologyNASDAQ
$6.05-0.17%
$0.01 (-0.17%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+81.8%upside
Target: $11.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SVRA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.99 – $6.11
TARGET (TP)$11.00
STOP LOSS$5.57
RISK/REWARD1:10.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.22
52W High$7.00
52W Low$1.89
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $257,000 |
| Gross Profit | $-78,029,000 | $-44,262,000 | $-27,879,000 | $-28,991,000 | $-34,781,000 |
| Gross Margin | N/A | N/A | N/A | N/A | -13533.5% |
| Operating Income | $-103,196,000 | $-60,007,000 | $-38,839,000 | $-41,477,000 | $-49,300,000 |
| Net Income | $-95,881,000 | $-54,698,000 | $-38,150,000 | $-43,014,000 | $-49,615,000 |
| Net Margin | N/A | N/A | N/A | N/A | -19305.4% |
| EPS | $-0.48 | $-0.33 | $-0.25 | $-0.32 | $-0.84 |
Company Overview
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
67%
Hold / Neutral
2
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
4 Bullish2 Neutral/Bearish
Price Targets
$5
Average Target
↓ 11.8% Downside
Now
$2
Low
$5
Average
$8
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 20th 2025 | Wells Fargo | Initiation | Overweight | $7 |
| August 15th 2025 | H.C. Wainwright | Upgrade | Buy | $5 |
| May 29th 2025 | H.C. Wainwright | Downgrade | Neutral | $2 |
| December 20th 2024 | Wells Fargo | Initiation | Overweight | $8 |
| November 13th 2024 | Evercore ISI | Downgrade | In-line | $5← $7 |
| February 15th 2024 | JMP Securities | Initiation | Mkt Outperform | $8 |
| November 7th 2023 | Guggenheim | Initiation | Buy | $7 |
| May 16th 2023 | Jefferies | Upgrade | Buy | $4← $2 |
| March 31st 2023 | Jefferies | Downgrade | Hold | $2 |
Earnings History & Surprises
SVRABeat Rate
32%
Last 19 quarters
Avg Surprise
-1.2%
EPS vs Estimate
Beats / Misses
6/7
6 met exactly
Latest EPS
$-0.14
Q4 2025
EPS Surprise History
Q1 24
+18.2%
$-0.09vs$-0.11
Q2 24
-10.0%
$-0.11vs$-0.10
Q3 24
-9.1%
$-0.12vs$-0.11
Q4 24
0.0%
$-0.11vs$-0.11
Q1 25
-18.2%
$-0.13vs$-0.11
Q2 25
0.0%
$-0.12vs$-0.12
Q3 25
-16.7%
$-0.14vs$-0.12
Q4 25
-7.7%
$-0.14vs$-0.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.12 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.13 | $-0.14 | -7.7% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.12 | $-0.12 | 0.0% | = MET |
Q1 2025 | Mar 27, 2025 | $-0.11 | $-0.13 | -18.2% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.11 | $-0.11 | 0.0% | = MET |
Q3 2024 | Aug 12, 2024 | $-0.11 | $-0.12 | -9.1% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.10 | $-0.11 | -10.0% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.07 | $-0.10 | -42.9% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.07 | $-0.07 | 0.0% | = MET |
Q1 2023 | Mar 30, 2023 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.07 | $-0.07 | 0.0% | = MET |
Q3 2022 | Aug 11, 2022 | $-0.06 | $-0.06 | 0.0% | = MET |
Q2 2022 | May 11, 2022 | $-0.08 | $-0.05 | +37.5% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $-0.07 | $-0.07 | 0.0% | = MET |
Q4 2021 | Nov 12, 2021 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.12 | $-0.07 | +41.7% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-0.08 | $-0.13 | -62.5% | ✗ MISS |
Latest News
Wells Fargo Maintains Overweight on Savara, Raises Price Target to $9
📈 PositiveBenzinga•Dec 18, 2025, 02:54 PM
European Patent Office Intends To Grant Savara Patent For Liquid Formulation Of MOLBREEVI
📈 PositiveBenzinga•Dec 11, 2025, 01:16 PM
Savara Inc. ticks higher amid takeover speculation
📈 PositiveSeeking Alpha•Dec 2, 2025, 07:39 PM
Savara, PARI Granted European Patent Titled 'Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution.'
📈 PositiveBenzinga•Dec 2, 2025, 01:31 PM
Oppenheimer Maintains Outperform on Savara, Raises Price Target to $9
📈 PositiveBenzinga•Nov 14, 2025, 05:30 PM
Citizens Maintains Market Outperform on Savara, Lowers Price Target to $10
📈 PositiveBenzinga•Nov 13, 2025, 03:01 PM
Savara Q3 EPS $(0.14) Misses $(0.13) Estimate
📉 NegativeBenzinga•Nov 12, 2025, 09:21 PM
Reported Earlier, Savara Announces $130M Public Offering Including 23.8M Shares And 7.1M Pre-Funded Warrants Priced At $4.20 Per Share
➖ NeutralBenzinga•Oct 30, 2025, 08:16 AM
Savara Announces Common Stock Offering; Terms Not Disclosed
📉 NegativeBenzinga•Oct 29, 2025, 08:08 PM
Savara Announces $75M Financing Agreement With RTW Investments
📈 PositiveBenzinga•Oct 29, 2025, 08:03 PM
Savara's Partner, TrilliumBiO, To Present Encore Data On Development Of Dried Blood Spot Test To Aid In Diagnosis Of aPAP, At CHEST 2025
📈 PositiveBenzinga•Oct 2, 2025, 08:09 PM
Savara Presents New Data From Phase 3 IMPALA-2 Showing Molgramostim Beneficial In aPAP Patients Regardless Of Disease Severity
📈 PositiveBenzinga•Sep 29, 2025, 07:22 AM
Guggenheim Maintains Buy on Savara, Raises Price Target to $11
📈 PositiveBenzinga•Sep 9, 2025, 01:00 PM
Oppenheimer Maintains Outperform on Savara, Raises Price Target to $8
📈 PositiveBenzinga•Sep 8, 2025, 12:22 PM
HC Wainwright & Co. Maintains Buy on Savara, Raises Price Target to $8
📈 PositiveBenzinga•Sep 3, 2025, 02:36 PM
Savara Reveals That The Results From The Phase 3 Impala-2 Clinical Trial Will Be Published Online In NEJM; In The Largest Clinical Trial Conducted In Autoimmune PAP, Molgramostim Inhalation Solution Reduced Surfactant Burden And Improved Pulmonary Gas Transfer, Respiratory Health-Related Quality Of Life, And Patient Functionality
📈 PositiveBenzinga•Aug 20, 2025, 09:19 PM
Savara Announces It Will Present New Data From Phase 3 IMPALA-2 Trial Of Molgramostim Inhalation Solution In Patients With Autoimmune Pulmonary Alveolar Proteinosis At European Respiratory Society Congress 2025
📈 PositiveBenzinga•Aug 18, 2025, 12:10 PM
Frequently Asked Questions about SVRA
What is SVRA's current stock price?
Savara Inc. (SVRA) is currently trading at $6.05 per share. The stock has moved -0.17% today.
What is the analyst price target for SVRA?
The average analyst price target for SVRA is $11.00, based on 1 analyst.
What sector is Savara Inc. in?
Savara Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SVRA's market cap?
Savara Inc. has a market capitalization of $1.23 billion, making it a small-cap company.
Does SVRA pay dividends?
No, Savara Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCAX
Bicara Therapeutics Inc. Common Stock
$17.60
Mkt Cap: $1.0B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
GERN
Geron Corporation
$1.33
Mkt Cap: $0.8B
GHRS
GH Research PLC
$12.96
Mkt Cap: $0.8B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
NBTX
Nanobiotix S.A.
$22.13
Mkt Cap: $1.1B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
Explore stocks similar to SVRA for comparison